Taggart “Tagg” McGurrinis a pharmaceutical executive with expertise spanning finance, law, pharmaceuticals, and biotech. His multidisciplinary background enables him to navigate the complex drug development and commercialization landscape.

McGurrin holds a dual BS/MBA in accounting, completed within four years. He began his career in banking at Bank of America, during which time he obtained his CPA certification. Following this, McGurrin earned a law degree from Temple University Beasley School of Law, further broadening his professional arsenal.

In March 2017, McGurrin transitioned to the pharmaceutical industry, joining a startup focused on developing non-opioid analgesics. This move aligned with his interest in addressing critical healthcare challenges, including the opioid crisis.

Throughout his tenure in pharma, McGurrin has served in key leadership roles as President, Chief Financial Officer, and Chief Operating Officer. His approach to these positions is characterized by comprehensive risk management, strategic financing, and ethical drug development. McGurrin emphasizes transparent investor relations while promoting a patient-focused approach to balance investor returns with positive health outcomes.

McGurrin's "creative pragmatism" governs his approach to solving industry challenges. He continues to focus on strategically financing and developing corporate strategy for high-growth pharma and biotech companies. Through his leadership, McGurrin strives to drive biotech innovation while maintaining a strong commitment to ethical drug development and patient welfare. He ultimately aims to align the interests of investors, patients, and regulatory bodies to drive sustainable progress within the pharmaceutical and biotech industries.